A chemical found in marijuana, known as tetrahydrocannabinol, or THC, has been found to potentially slow the process in which mental decline can occur in up to 50 percent of HIV patients, says a new Michigan State University study.
“It’s believed that cognitive function decreases in many of those with HIV partly due to chronic inflammation that occurs in the brain,” said Norbert Kaminski, lead author of the study, now published in the journal AIDS. “This happens because the immune system is constantly being stimulated to fight off disease.”
Kaminski and his co-author, Mike Rizzo, a graduate student in toxicology, discovered that the compounds in marijuana were able to act as anti-inflammatory agents, reducing the number of white blood cells, called monocytes, and decreasing the proteins they release that cause inflammatory responses in the body.
“This decrease of cells could slow down, or maybe even stop, the inflammatory process, potentially helping patients maintain their cognitive function longer,” Rizzo said.
The two researchers took blood samples from 40 HIV patients who reported whether or not they used marijuana. Then, they isolated the white blood cells from each donor and studied inflammatory cell levels and the effect marijuana had on the cells.
“The patients who didn’t smoke marijuana had a very high level of inflammatory cells compared to those who did use,” Kaminski said. “In fact, those who used marijuana had levels pretty close to a healthy person not infected with HIV.”
Kaminski, director of MSU’s Institute for Integrative Toxicology, has studied the effects of marijuana on the immune system since 1990. His lab was the first to identify the proteins that can bind marijuana compounds onto immune cells. Up until then, it was unclear how these compounds, also known as cannabinoids, affected the immune system.
HIV, which stands for human immunodeficiency